gp100 (182-191)

gp100 (182-191) is a synthetic peptide corresponding to amino acids 182 through 191 of the human gp100 protein, a melanocyte differentiation antigen widely studied in immunology and cancer research. As a defined epitope recognized by cytotoxic T lymphocytes, this peptide holds particular significance in the investigation of antigen processing, immune recognition, and T cell activation mechanisms. Its well-characterized sequence makes it a valuable tool for dissecting peptide-MHC interactions, exploring antigen-specific responses, and supporting the development of immunological assays. The biochemical stability and sequence specificity of gp100 (182-191) facilitate its use in a range of experimental systems, enabling researchers to probe fundamental questions in cellular immunology and antigen presentation.

Immunological Assay Development: The gp100 (182-191) peptide is widely utilized in the development and optimization of immunological assays, such as ELISPOT, intracellular cytokine staining, and flow cytometry-based detection of antigen-specific T cells. By serving as a defined target for cytotoxic T lymphocyte (CTL) recognition, it enables precise quantification and characterization of T cell responses in vitro. This application is particularly relevant in studies aiming to monitor immune activation, profile T cell specificity, or validate the efficacy of antigen presentation in experimental models.

Epitope Mapping and TCR Specificity Studies: Researchers employ this peptide to map T cell epitopes and investigate the specificity of T cell receptors (TCRs) for the gp100 antigen. Its defined sequence allows for the systematic evaluation of TCR recognition patterns, cross-reactivity, and the identification of immunodominant regions within the gp100 protein. These studies are essential for elucidating the molecular basis of antigen recognition and for informing the rational design of peptide-based immunotherapies and vaccines.

Antigen Processing and Presentation Analysis: The peptide is instrumental in dissecting the mechanisms of antigen processing and presentation by major histocompatibility complex (MHC) class I molecules. By using gp100 (182-191) in cellular systems, investigators can assess the efficiency of peptide loading onto MHC molecules, determine the impact of antigen processing machinery, and evaluate the influence of cellular context on antigen presentation. Such analyses contribute to a deeper understanding of how peptide antigens are generated and displayed to the immune system.

Ex Vivo Functional T Cell Activation: In ex vivo experimental setups, the peptide is commonly used to stimulate peripheral blood mononuclear cells (PBMCs) or isolated T cells from human donors or experimental animals. This approach enables the assessment of T cell activation, cytokine production, proliferation, and cytotoxic function in response to a well-defined antigenic stimulus. The resulting data provide valuable insights into immune competence, antigen-specific memory, and the dynamics of cellular immunity under various experimental conditions.

Peptide-Based Vaccine Research: The defined immunogenic properties of gp100 (182-191) support its use in preclinical research focused on the design and evaluation of peptide-based vaccines. By serving as a model epitope, it allows researchers to investigate parameters influencing immunogenicity, such as adjuvant formulation, delivery systems, and sequence modifications. These studies inform the optimization of peptide vaccines and advance the broader understanding of antigen-driven immune responses, particularly in the context of tumor immunology and antigen-specific immunotherapy development.

1. Emu oil in combination with other active ingredients for treating skin imperfections

2. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function

3. Immune responses to peptides containing homocitrulline or citrulline in the DR4-transgenic mouse model of rheumatoid arthritis

4. Implications of ligand-receptor binding kinetics on GLP-1R signalling

5. Investigating Potential Interactions Between Neurohypophyseal Peptides, their Drug Analogs, and Coagulation Factor VIII